Finding the Optimal Regimen for Short-Term Daily Recombinant Human Erythropoietin Treatment for Blood-Saving Purpose in Patients undergoing Unilateral Primary Total Hip Arthroplasty: A Double-Blinded Randomized Placebo-Controlled Trial